Scientists find hidden immune hubs in the skull that fight brain cancer

Researchers at Washington University School of Medicine in St. Louis have identified immune structures inside skull bone marrow that respond to brain cancer faster than the body’s distant lymph nodes do. The structures resemble lymph nodes themselves, organizing T follicular helper cells and antibody-producing B cells in a pattern the team says had never been documented in healthy bone marrow before. In mice with glioblastoma, disrupting these hubs sped up tumor growth and shortened survival, evidence the researchers say points to a previously unrecognized layer of the brain’s immune defense.

The findings, published in the journal Nature, grew out of an effort to trace how proteins move from brain tissue through the skull and its surrounding membranes. Jonathan Kipnis, a professor of pathology and immunology at Washington University and the study’s senior author, has spent much of his career studying unexpected channels between the brain and the immune system, and this discovery extends that line of research into bone marrow most scientists assumed served a purely structural role.

Structures That Look Like Lymph Nodes

“The skull bone marrow is far more than just a structural framework — it harbors previously unrecognized hubs for brain-specific immune responses,” Kipnis said, according to details reported by ScienceDaily. Jang Hyun Park, the study’s first author and a postdoctoral fellow in Kipnis’s lab, said the organization inside the marrow surprised even researchers who expected to find something, since nothing resembling it had turned up in healthy bone marrow before this study. “It is an exciting discovery that points out that a complex brain requires its own specialized immune structures to defend it,” Park said.

Responding to Brain Cancer Before Lymph Nodes Do

The team’s central finding was one of timing as much as location. “These nearby immune hubs can respond rapidly to brain cancer, becoming active before more distant lymph nodes even receive signals that something is wrong,” the researchers said in a summary of the work published by Washington University. That proximity, sitting just beyond the dura mater rather than deep in the neck or chest, appears to give the skull marrow a head start most other immune tissue in the body does not have when a tumor begins growing inside the brain.

To confirm the hubs mattered functionally and not just anatomically, the researchers pharmacologically disrupted them in mice carrying glioblastoma tumors. Tumors grew faster and the animals survived for shorter periods once the hubs were disabled, a direct test of cause and effect rather than a correlation drawn from imaging alone.

A Gel Under the Scalp, Tested in Mice

Beyond disrupting the hubs, the team also tried strengthening them. They developed a gel containing three immune-boosting proteins and applied it beneath the scalp of tumor-bearing mice, positioning the treatment as close as possible to the newly identified marrow structures. The gel triggered an immune surge inside the skull hubs that preceded any response in the animals’ more distant lymph nodes, and mice that received it survived longer than untreated controls, according to the EurekAlert summary of the paper.

The approach matters clinically because it suggests treatments could be delivered close to the skull rather than injected or infused systemically throughout the body, potentially reducing the wider side effects of therapies meant to rev up the immune system across the whole body rather than at a single site.

Glioblastoma, the tumor type used in the mouse experiments, remains one of the deadliest cancers in adults. Most patients survive well under two years after diagnosis despite decades of surgical and drug advances, a grim baseline that is part of why a new avenue for reaching the brain’s immune defenses drew attention from researchers outside Kipnis’s own lab.

Beyond Glioblastoma

The researchers also reported finding immune cells resembling the mouse structures in human skull bone marrow samples, an early but important signal that the discovery may not be confined to laboratory animals. Kipnis said the implications could extend well past brain cancer, since the brain’s reliance on first responders in the surrounding skull could reshape how therapies are designed for conditions including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and long COVID, he said, according to the Hope Center for Neurological Disorders, which co-funded the work through Washington University.

The research drew support from South Korea’s National Institute of Health, the Cure Alzheimer’s Fund, and the National Research Foundation of Korea, reflecting the international scope of Kipnis’s lab, where Park is now finishing his postdoctoral work before opening an independent lab at the Korea Advanced Institute of Science and Technology. Whether the skull’s immune hubs can actually be targeted in human patients, and whether boosting them produces the same survival benefit seen in mice, remains to be tested, according to the Office of Neuroscience Research at Washington University, which described the finding as a starting point rather than a finished therapy.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview